Neumega (Genetics Institute Inc)

Neumega (Genetics Institute Inc) - General Information

Neumega (Genetics Institute Inc), the active ingredient in Neumega® is recombinant Interleukin eleven, which is produced in Escherichia coli (E. coli) by recombinant DNA technology. The protein has a molecular mass of approximately 19,000 daltons, and is non-glycosylated. The polypeptide is 177 amino acids in length (the natural IL-11 has 178). This alteration has not resulted in measurable differences in bioactivity either in vitro or in vivo.
The primary hematopoietic activity of Neumega® is stimulation of megakaryocytopoiesis and thrombopoiesis. In mice and nonhuman primate studies Neumega® has shown potent thrombopoietic activity in compromised hematopoiesis, including moderately to severely myelosuppressed animals. In these studies, Neumega® improved platelet nadirs and accelerated platelet recoveries compared to controls.
In animal studies Neumega (Genetics Institute Inc) also has non-hematopoetic activities. This includes the regulation of intestinal epithelium growth (enhanced healing of gastrointestinal lesions), the inhibition of adipogenesis, the induction of acute phase protein synthesis (e.g., fibrinogen), and inhibition of macrophageal released pro-inflammatory cytokines.

Pharmacology of Neumega (Genetics Institute Inc)

Neumega (Genetics Institute Inc) is indicated for the prevention of severe thrombocytopenia and the reduction of the need for platelet transfusions following myelosuppressive chemotherapy in adult patients with nonmyeloid malignancies who are at high risk of severe thrombocytopenia. The primary hematopoietic activity of Neumega (Genetics Institute Inc) is stimulation of megakaryocytopoiesis and thrombopoiesis. Neumega (Genetics Institute Inc) has shown potent thrombopoietic activity in individuals with compromised hematopoiesis

Neumega (Genetics Institute Inc) for patients

Neumega (Genetics Institute Inc) Interactions

Most patients in trials evaluating Neumega were treated concomitantly with filgrastim (G-CSF) with no adverse effect of Neumega on the activity of G-CSF. No information is available on the clinical use of sargramostim (GM-CSF) with Neumega in human subjects. However, in a study in nonhuman primates in which Neumega and GM-CSF were coadministered, there were no adverse interactions between Neumega and GM-CSF and no apparent difference in the pharmacokinetic profile of Neumega.

Drug interactions between Neumega and other drugs have not been fully evaluated. Based on in vitro and nonclinical in vivo evaluations of Neumega, drug-drug interactions with known substrates of P450 enzymes would not be predicted.

Neumega (Genetics Institute Inc) Contraindications

Neumega is contraindicated in patients with a history of hypersensitivity to Neumega or any component of the product.

Additional information about Neumega (Genetics Institute Inc)

Neumega (Genetics Institute Inc) Indication: Increases reduced platelet levels due to chemotherapy
Mechanism Of Action: Neumega (Genetics Institute Inc) binds to the interleukin 11 receptor which leads to a cascade of signal transduction events. IL-11 is a thrombopoietic growth factor that directly stimulates the proliferation of hematopoietic stem cells and megakaryocyte progenitor cells and induces megakaryocyte maturation resulting in increased platelet production.
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Oprelvekin
Synonyms: AGIF; Adipogenesis inhibitory factor; IL-11; Interleukin-11 precursor
Drug Category: Coagulants; Thrombotics
Drug Type: Biotech; Approved; Investigational

Other Brand Names containing Oprelvekin: Neumega (Genetics Institute Inc);
Absorption: Absolute bioavailability is over 80%.
Toxicity (Overdose): Not Available
Protein Binding: Not Available
Biotransformation: Not Available
Half Life: 6.9 +/- 1.7 hrs
Dosage Forms of Neumega (Genetics Institute Inc): Injection, powder, lyophilized, for solution Subcutaneous
Chemical IUPAC Name: Human interleukin 11
Chemical Formula: C854H1411N253O235S2
Oprelvekin on Wikipedia: https://en.wikipedia.org/wiki/Oprelvekin
Organisms Affected: Humans and other mammals